help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gabrilove, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gabrilove, J. L.
The Oncologist, Vol. 6, Suppl 5, 4-7, October 2001
© 2001 AlphaMed Press

Angiogenic Growth Factors: Autocrine and Paracrine Regulation of Survival in Hematologic Malignancies

Janice L. Gabrilove

Division of Medical Oncology, Department of Medicine, The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York, USA

Correspondence: Janice L. Gabrilove, M.D., Chief, Division of Medical Oncology, Department of Medicine, Deputy Director for Clinical Affairs, The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029, USA. Telephone: 212-241-9650; Fax: 212-289-0678; e-mail: janice.gabrilove{at}mssm.edu

Recent research has focused on the role of angiogenic growth factors and their ability to mediate tumor growth and metastases, both in solid tumors and in hematologic malignancies. The bone marrow microenvironment is the setting for a wealth of complex interactions that include cell-to-cell contacts as well as secretion of and response to soluble factors. Abundant evidence supports the role of basic fibroblast growth factor (bFGF) in contributing to the dysregulation of apoptosis that is the hallmark of chronic lymphocytic leukemia (CLL). In fact, CLL cells themselves express bFGF; intracellular levels of this cytokine correlate with clinical CLL stage. Other stromal factors mediate the inhibition of apoptosis in CLL as well, suggesting that strategies to block the responses of CLL cells to these factors may represent effective therapies. More broadly, the class of agents known as angiogenesis inhibitors may offer important advantages with respect to the treatment of numerous types of malignancies. Currently, a number of clinical trials are under way to evaluate the clinical potential of several different angiogenesis inhibitors in several hematologic neoplasms.

Key Words. Cancer • Leukemia • Myelodysplastic syndromes • Chemotherapy • Angiogenesis




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
B. F. Taylor, S. C. McNeely, H. L. Miller, G. M. Lehmann, M. J. McCabe Jr., and J. C. States
p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21CIP1/WAF1
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 142 - 151.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
T. Wasil and S. M. Lichtman
Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Oncologist, September 1, 2005; 10(8): 602 - 612.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Gridelli and F. A. Shepherd
Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer: A Review of the Evidence
Chest, August 1, 2005; 128(2): 947 - 957.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Vincent, D. K. Jin, M. A. Karajannis, K. Shido, A. T. Hooper, W. K. Rashbaum, B. Pytowski, Y. Wu, D. J. Hicklin, Z. Zhu, et al.
Fetal Stromal-Dependent Paracrine and Intracrine Vascular Endothelial Growth Factor-A/Vascular Endothelial Growth Factor Receptor-1 Signaling Promotes Proliferation and Motility of Human Primary Myeloma Cells
Cancer Res., April 15, 2005; 65(8): 3185 - 3192.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. D. Ramsey, N. Howlader, R. D. Etzioni, and B. Donato
Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non-Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results-Medicare
J. Clin. Oncol., December 15, 2004; 22(24): 4971 - 4978.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. G. Azzoli, D. G. Pfister, D. H. Johnson, and M. R. Somerfield
In Reply:
J. Clin. Oncol., December 15, 2004; 22(24): 5020 - 5021.
[Full Text] [PDF]


Home page
The OncologistHome page
P. D. Makrantonakis, E. Galani, and P. G. Harper
Non-Small Cell Lung Cancer in the Elderly
Oncologist, September 1, 2004; 9(5): 556 - 560.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. C. R. Santos and S. Dias
Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways
Blood, May 15, 2004; 103(10): 3883 - 3889.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]


Home page
The OncologistHome page
B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach
Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer
Oncologist, June 1, 2003; 8(3): 270 - 277.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G.-Q. Chen, L. Zhou, M. Styblo, F. Walton, Y. Jing, R. Weinberg, Z. Chen, and S. Waxman
Methylated Metabolites of Arsenic Trioxide Are More Potent Than Arsenic Trioxide as Apoptotic but not Differentiation Inducers in Leukemia and Lymphoma Cells
Cancer Res., April 15, 2003; 63(8): 1853 - 1859.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
P. A. Bunn Jr. and R. Lilenbaum
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer
J Natl Cancer Inst, March 5, 2003; 95(5): 341 - 343.
[Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2001 by AlphaMed Press.